You may have questions about PLUVICTO
Click on the questions below to find the answers to some frequently asked questions.
Lutetium-177 is the radioactive particle in PLUVICTO. The full name of the PLUVICTO molecule is lutetium Lu 177 vipivotide tetraxetan.
PLUVICTO is a prescription medicine. It is used to treat men with PSMA+ metastatic castration-resistant prostate cancer (mCRPC). These men have already taken hormone therapy and chemotherapy.
PLUVICTO is a radioligand therapy (RLT). RLT is a different type of radiation therapy that is injected and that targets a biomarker called PSMA which is present on many prostate cancer cells and also some healthy cells. This means it is designed to find and attack PSMA+ cells, including cancer cells*.
*Noncancerous PSMA+ cells and other surrounding healthy cells may also be damaged.
PSMA (prostate-specific membrane antigen) is a biomarker that can be found on prostate cancer cells, including those that have spread. A plus sign (+) following PSMA means enough PSMA was found to classify a patient as PSMA positive.
You can find out if you’re PSMA+ with a PSMA-PET scan. It checks for PSMA+ cells in your body.
You may be eligible if you have:
Metastatic castration-resistant prostate cancer (mCRPC)
PSMA+ prostate cancer
Been treated with hormone therapy (pills) and chemotherapy
No, PLUVICTO is a radioligand therapy (RLT).
RLT is a different type of radiation therapy that is injected and that targets a biomarker called PSMA, which is present in more than 80% of men with prostate cancer. PSMA is found on many prostate cancer cells and also some healthy cells. This means that PLUVICTO is designed to find and attack PSMA+ cells, including cancer cells.*
*Noncancerous PSMA+ cells and other surrounding healthy cells may also be damaged.
The most common side effects of PLUVICTO include:
Fatigue
Dry mouth
Nausea
Decreased appetite
Constipation
Anemia
These are not all of the possible side effects of PLUVICTO. Visit PLUVICTO Side Effects for more information.
PLUVICTO is given as an intravenous (IV) infusion. Your health care provider will determine the appropriate dosage and schedule.
Your doctor will decide on the best treatment plan for you. It’s important to discuss all treatments and medications with your doctor. This will help ensure there are no interactions.
Novartis Patient Support can connect you with financial assistance, support groups, and educational materials. Contact Novartis Patient Support for more information.